# Francesco Facchinetti

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/francesco-facchinetti/

## Facts

| Field | Value |
| --- | --- |
| Citations | 4,030 |
| Field | Fibroblast Growth Factor Research |
| h-index | 35 |
| i10-index | 73 |
| Last Known Institution | Dana-Farber Cancer Institute |
| OpenAlex ID | https://openalex.org/A5009379815 |
| ORCID iD | 0000-0001-6313-6341 |
| Works | 319 |

## Researcher papers

- [Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?](https://scholariq.org/papers/making-the-first-move-in-egfr-driven-or-alk-driven-nsclc-first-generation-or/)
- [Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer](https://scholariq.org/papers/diverse-resistance-mechanisms-to-the-third-generation-alk-inhibitor-lorlatinib/)
- [BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall](https://scholariq.org/papers/braf-in-non-small-cell-lung-cancer-nsclc-pickaxing-another-brick-in-the-wall/)
- [Transferrin receptor targeting chimeras for membrane protein degradation](https://scholariq.org/papers/transferrin-receptor-targeting-chimeras-for-membrane-protein-degradation/)
- [Crizotinib-Resistant <i>ROS1</i> Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for <i>ROS1</i> - and <i>ALK</i> -Rearranged Lung Cancers](https://scholariq.org/papers/crizotinib-resistant-i-ros1-i-mutations-reveal-a-predictive-kinase-inhibitor/)
- [First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status](https://scholariq.org/papers/first-line-pembrolizumab-in-advanced-non-small-cell-lung-cancer-patients-with/)
- [The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer](https://scholariq.org/papers/the-clinical-landscape-of-cell-free-dna-alterations-in-1671-patients-with/)
- [The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC](https://scholariq.org/papers/the-circulating-pool-of-functionally-competent-nk-and-cd8-cells-predicts-the/)
- [Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors](https://scholariq.org/papers/facts-and-new-hopes-on-selective-fgfr-inhibitors-in-solid-tumors/)
- [Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy](https://scholariq.org/papers/primary-resistance-to-osimertinib-due-to-sclc-transformation-issue-of-t790m/)

## Researcher topics

- [Fibroblast Growth Factor Research](https://scholariq.org/topics/fibroblast-growth-factor-research/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)
- [Urinary and Genital Oncology Studies](https://scholariq.org/topics/urinary-and-genital-oncology-studies/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

## Researcher university

- [Dana-Farber Cancer Institute](https://scholariq.org/institutions/dana-farber-cancer-institute/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.